As the Ebola crisis deepens in the Democratic Republic of Congo, there are flickers of hope amid the despair. Survivors emerging from treatment centres represent a small but significant return on a massive investment of international aid. But the bottom line remains grim: this outbreak is proving to be one of the most stubborn in history, and the capital of global goodwill is being drawn down at an alarming rate.
At the epicentre in North Kivu, health workers report that some patients are now surviving the virus. These survivors, however, are not simply discharged. They become ambassadors of a grim fiscal reality: the cost of containing this outbreak is spiralling. The World Health Organisation has already spent over $100 million, with no end in sight. The survivors are a small dividend on that expenditure, but the yield is dangerously low.
The market for global health security is characterised by volatility. One survivor’s story can boost donor morale, but the next cluster of cases can send risk premiums soaring. The DRC’s government, already stretched by conflict and poverty, is effectively bankrupt in terms of healthcare capacity. International agencies are providing the liquidity, but the sustainability of this bailout is questionable.
Gilt yields for humanitarian bonds, if they existed, would be sky-high right now. The fear of contagion spreading to larger cities like Goma has prompted a massive injection of funds, but the return on that investment is measured in lives saved, not profits. That is a difficult metric to market to fiscal hawks. The efficiency of spending is further undermined by the security situation: armed groups attack health workers, causing delays and cost overruns.
Yet there is a bullish case. The survivors, once recovered, can provide valuable data on immunity and treatment protocols. They are assets in the fight against misinformation, which is as dangerous as the virus itself. A survivor speaking out can boost vaccine uptake, lowering the long-term liability of future outbreaks. But this is a long-run payoff, and the short-term pain is acute.
The central bank of global health, if there were one, would be printing currency in the form of emergency authorisations for experimental treatments. But this quantitative easing carries its own risks: side effects, unknown efficacy, and the moral hazard of relying on unproven therapies. The market is pricing in high uncertainty.
In the meantime, the survivors’ moments of hope are real and valuable. They are the only dividends we have against a backdrop of rising case counts. But for anyone concerned with fiscal responsibility, the books on this outbreak do not balance. The deficit of lives lost and dollars spent continues to widen. The only way to make the numbers work is a long-term investment in health systems, but that requires a degree of political will that is currently in short supply.
The bottom line is this: Ebola survivors are a rare bright spot in a dark fiscal picture. But without a more efficient allocation of resources and a sustainable funding model, hope alone will not stop the hemorrhaging.
